Why the study?
Gaps remain in understanding the pathophysiology of DKD, and current clinical diagnostic methods and treatment strategies have drawbacks.
Answers are grounded in this paper and cite their sources.
Long non-coding RNAs play a significant role in the pathophysiology of diabetic kidney disease and hold potential as diagnostic biomarkers and therapeutic targets.
Diabetic kidney disease (DKD), one of the common microvascular complications of diabetes, is increasing in prevalence worldwide and can lead to End-stage renal disease. However, there are still gaps in our understanding of the pathophysiology of DKD, and both current clinical diagnostic methods and treatment strategies have drawbacks. According to recent research, long non-coding RNAs (lncRNAs) are intimately linked to the developmental process of DKD and could be viable targets for clinical diagnostic decisions and therapeutic interventions. Here, we review recent insights gained into lncRNAs in pathological changes of DKD such as mesangial expansion, podocyte injury, renal tubular injury, and interstitial fibrosis. We also discuss the clinical applications of DKD-associated lncRNAs as diagnostic biomarkers and therapeutic targets, as well as their limitations and challenges, to provide new methods for the prevention, diagnosis, and treatment of DKD.
No takes yet. Share an insight, caveat, or question.
Hou et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: